Next-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank

Abstract

IntroductionOur efforts to prevent and treat breast cancer are significantly impeded by a lack of knowledge of the biology and developmental genetics of the normal mammary gland. In order to provide the specimens that will facilitate such an understanding, The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center (KTB) was established. The KTB is, to our knowledge, the only biorepository in the world prospectively established to collect normal, healthy breast tissue from volunteer donors. As a first initiative toward a molecular understanding of the biology and developmental genetics of the normal mammary gland, the effect of the menstrual cycle and hormonal contraceptives on DNA expression in the normal breast epithelium was examined.MethodsUsing normal breast tissue from 20 premenopausal donors to KTB, the changes in the mRNA of the normal breast epithelium as a function of phase of the menstrual cycle and hormonal contraception were assayed using next-generation whole transcriptome sequencing (RNA-Seq).ResultsIn total, 255 genes representing 1.4% of all genes were deemed to have statistically significant differential expression between the two phases of the menstrual cycle. The overwhelming majority (221; 87%) of the genes have higher expression during the luteal phase. These data provide important insights into the processes occurring during each phase of the menstrual cycle. There was only a single gene significantly differentially expressed when comparing the epithelium of women using hormonal contraception to those in the luteal phase.ConclusionsWe have taken advantage of a unique research resource, the KTB, to complete the first-ever next-generation transcriptome sequencing of the epithelial compartment of 20 normal human breast specimens. This work has produced a comprehensive catalog of the differences in the expression of protein-coding genes as a function of the phase of the menstrual cycle. These data constitute the beginning of a reference data set of the normal mammary gland, which can be consulted for comparison with data developed from malignant specimens, or to mine the effects of the hormonal flux that occurs during the menstrual cycle.

Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer

“…Functional limitations and sarcopenia are the validated systemic effects of breast cancer (5,38). However, to our knowledge, none of the currently available transgenic models have been used to understand these systemic effects and to test for therapies that have dual effects on cancer and systemic effects or that may complement chemotherapy to improve quality of life.…”

Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling

“…Although human studies of altered hepatic metabolism with lactation have not been performed, there is also evidence that prolactin can alter drug-metabolizing hepatic enzymes (57). A further consideration is that the mRNA of many CYP enzymes, including 1B1 and 2C, has been identified in mammary tissues and the fat layer of human milk (58-60), with CYP1B1 having the highest mRNA expression of all CYP enzymes in mammary tissue (59). Given the proliferation of mammary cells that occurs in pregnancy, the increased presence of these enzymes in breast tissue may also help explain the reduction in systemic PYR exposure during pregnancy.…”

An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival

“…A recent RNA-seq study of normal human breast tissues from a small number of healthy premenopausal individuals in two phases of the menstrual cycle did not report fluctuations in interferon related genes as a function of estrous stage [46]. A more detailed comparison between this data set and ours is warranted, using a common RNA-seq analyses method to provide a valid comparison.…”